PharmaJet is a private drug delivery technology company which has developed a family of patented, proprietary needle-free injection technologies, able to deliver injection of liquid medicines into the body.

Our core technology provides for fixed dosage delivery, which is particularly well suited for injection of vaccines. The sterile syringe is designed for single use, and has an auto-disable feature, thus addressing the elimination of needles, needle re-use and needle stick injury in a revolutionary way. In 2004, PharmaJet received its first 510(k) marketing clearance from the FDA, with designation as a class II medical device.

PharmaJet’s approach to needle-free holds benefit for all constituencies — whether patient or care-giver, vaccine maker or government, researcher or practitioner, hospital or insurer. The Company’s technology is being tested by numerous makers of vaccines and therapeutics, universities, and governments, to address clean delivery of injectable medicines — whether in the clinic or for mass vaccination programs, or in the home environment, or for promising new site-specific applications.

Exciting evidence of “dose sparing” potential with PharmaJet’s intra-dermal injector technology suggests that vaccine expenditures may be reduced, allowing for better utilization of vaccine resources, or expenditures to be redirected to other health initiatives. With mounting evidence from each test completed, we are coming closer to realizing our mission, which is to become the global standard for needle-free vaccine delivery — and our vision, which is to break the world-wide cycle of poverty, disease, and economic loss caused by needle re-use and needle-stick injury.